【财华社讯】东阳光药(06887.HK)公布，董事会接获公司控股股东集团成员张寓帅及郭梅兰告知，鉴于 郭梅兰决定退休并减少参与集团业务，于2025年12月29日，张寓帅与郭梅兰订立股权转让协议，据此郭 梅兰将其分别于乳源寓能电子及乳源新京科技持有的71.75%股权及74.63%股权转让张寓帅，转让之名 义代价各分别为人民币1.00元。郭梅兰为张寓帅的母亲。 完成相关监管备案及股权转让交割后，张寓帅将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭梅兰将不再为控股股东集团成员。 董事认为，股权转让对公司整体财务及营运不会产生任何不利影响。 本文源自：财华网 ...

董事认为，股权转让对本公司整体财务及营运不会产生任何不利影响。 智通财经APP讯，东阳光药(06887)发布公告，本公司董事会接获张寓帅先生(张先生)及郭梅兰女士(郭女 士)(各自作为本公司的控股股东集团成员)(控股股东)告知，鉴于郭女士决定退休并减少参与本集团业 务，于2025年12月29日，张先生与郭女士订立股权转让协议，郭女士将其分别于乳源瑶族自治县寓能电 子实业有限公司(乳源寓能电子)及乳源瑶族自治县新京科技发展有限公司(乳源新京科技)持有的71.75% 股权及74.63%股权转让张先生，转让的名义代价各分别为人民币1.00元(股权转让)。郭女士为张先生的 母亲。 完成相关监管备案及股权转让交割后，张先生将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭女士将不再为控股股东集团成员。 ...

董事认为，股权转让对本公司整体财务及营运不会产生任何不利影响。 完成相关监管备案及股权转让交割后，张先生将分别持有乳源寓能电子及乳源新京科技99.2%及75.0% 股权，从而成为控股股东集团的新领导人，而郭女士将不再为控股股东集团成员。 东阳光（600673）药(06887)发布公告，本公司董事会接获张寓帅先生(张先生)及郭梅兰女士(郭女士)(各 自作为本公司的控股股东集团成员)(控股股东)告知，鉴于郭女士决定退休并减少参与本集团业务，于 2025年12月29日，张先生与郭女士订立股权转让协议，郭女士将其分别于乳源瑶族自治县寓能电子实业 有限公司(乳源寓能电子)及乳源瑶族自治县新京科技发展有限公司(乳源新京科技)持有的71.75%股权及 74.63%股权转让张先生，转让的名义代价各分别为人民币1.00元(股权转让)。郭女士为张先生的母亲。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 內幕消息 控股股東集團成員間的股權轉讓 本 公 告 乃 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱 「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例第XIVA部下的內幕消息條文（ 定義見上市規則 ） 而作出。 股權轉讓 本公司董事（「董事」）會（「董事會」）接獲張寓帥先生（「張先生」）及郭梅蘭女士（「郭 女士」）（ 各自作為本公司之控股股東集團成員（ 定義見上市規則 ））（「控股股東」）告 知 ， 鑒 於 郭 女 士 決 定 ...

Core Viewpoint - The article highlights the low flu vaccine uptake in China, driven by widespread vaccine hesitancy among the population, including healthcare professionals, despite the availability of free vaccines for vulnerable groups [1][6][14]. Group 1: Vaccine Market Dynamics - The three main companies relying on flu vaccine sales in China are Hualan Biological (10.7 billion), Zhonghui Biological (2.6 billion), and Jindike (808 million), with a combined annual sales of approximately 14 billion [3]. - In contrast, the leading flu medication company, Dongyangguang Pharmaceutical, reported annual sales of around 26 billion for its flu drug Oseltamivir [3]. - The article notes a significant disparity between the sales of flu vaccines and flu medications, with the latter being preferred by consumers due to immediate symptom relief [3][13]. Group 2: Reasons for Vaccine Hesitancy - Vaccine hesitancy is attributed to several factors, including doubts about vaccine effectiveness and safety, as well as a lack of awareness regarding the severity of flu [9][10]. - Many individuals, including healthcare workers, express skepticism about the flu vaccine's ability to prevent infection, leading them to rely on medications instead [9][10]. - A study indicated that over half of social media users exhibit flu vaccine hesitancy, primarily due to distrust in vaccine efficacy and safety [10][11]. Group 3: Public Health Implications - The low flu vaccine uptake has resulted in significant public health concerns, with over 200,000 excess deaths related to flu annually in China [14]. - The Chinese flu vaccine uptake rate remains around 3%, which is significantly lower than global averages, highlighting the urgent need for improved public health strategies [14][16]. - Recent initiatives by health authorities aim to enhance vaccine accessibility and encourage healthcare workers to lead by example in promoting flu vaccination [16].

Core Viewpoint - The article highlights the stark contrast between the low sales of flu vaccines and the high sales of flu medications in China, primarily due to widespread vaccine hesitancy among the population, including healthcare professionals [2][10]. Vaccine Market Analysis - The annual sales of flu vaccines from three leading companies in China—Hualan Biological (10.7 billion), Zhonghui Biological (2.6 billion), and Jindike (808 million)—total approximately 1.4 billion, which is only about half of the annual sales of flu medication from Dongyangguang Pharmaceutical, which stands at around 2.6 billion [1][11]. - The flu vaccine uptake in China is extremely low, with a reported vaccination rate of only about 3%, significantly below global averages [11][12]. Vaccine Hesitancy Factors - Vaccine hesitancy is attributed to several factors, including doubts about vaccine safety and effectiveness, the perception that flu vaccines do not prevent infection due to the virus's constant mutation, and a preference for immediate medication over preventive measures [6][8]. - A study indicated that over half of social media users exhibit flu vaccine hesitancy, primarily due to distrust in vaccine efficacy and safety, exacerbated by misinformation [7][8]. Healthcare Professionals' Attitudes - Many healthcare professionals, including doctors, show reluctance to receive flu vaccinations, with some citing personal experiences and a belief in their own immunity as reasons for not vaccinating themselves or their children [3][4][6]. - A significant number of medical staff do not participate in vaccination programs, even when offered for free, indicating a broader issue of vaccine acceptance within the healthcare community [4][5]. Public Health Implications - The low vaccination rates have led to preventable illnesses and deaths, with estimates suggesting over 200,000 excess deaths annually due to flu-related complications in China [11]. - Recent initiatives by health authorities aim to improve vaccination rates by integrating flu vaccine prescriptions into routine medical care and encouraging healthcare workers to lead by example [12].

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) is a leading company in the influenza sector with a solid foundation and a rich pipeline of innovative products, focusing on three main areas: anti-infection, chronic diseases, and oncology. The company maintains a leading position in the anti-infection field, particularly in influenza, hepatitis C, and hepatitis B, and has been given a "Buy" rating by Huafu Securities [1]. Group 1: Anti-Infection - The company holds a leading position in the influenza market, with Oseltamivir ranking first in domestic market share and possessing the largest production base globally, ensuring sufficient supply capacity [2]. - The hepatitis C pipeline includes the approval of pan-genotypic therapies, with NMPA approvals for Phosphoribosyl-1-pyrophosphate and Acalabrutinib expected in February and March 2025, respectively [2]. - For hepatitis B, the fastest progress is seen with Mofetil, which is the only product in China entering Phase III clinical trials, while the siRNA therapy (HECN30227) is set to enter clinical stages in October 2025 [2]. Group 2: Chronic Diseases - Ifenprodil is identified as a potential blockbuster drug (BIC) targeting the $4 billion global market for idiopathic pulmonary fibrosis, with Phase I trials completed in China and the US, and promising Phase II data showing a 96% delay in decline compared to placebo [3]. - Insulin products are nearing FDA approval, with Glargine expected to receive BLA approval in the first half of 2026, while Aspart has a Pre-IND application submitted, with plans to file for BLA by the end of 2025 and anticipate approval by the end of 2026 [3]. Group 3: Oncology - The company expects the approval of Clifosfamide for acute myeloid leukemia (AML) by 2027, having formed a partnership with 3SBio for this product [4]. - The oncology pipeline is rich, including Lenvatinib (Phase III) for esophageal cancer, HEC53856 (Phase II) for chemotherapy-induced anemia, and HEC201625 (upcoming IND) as an oral PD-L1 small molecule, with ongoing efforts in new technology areas such as ADC and TCE [4]. Group 4: Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 250 million, 540 million, and 930 million yuan for the years 2025, 2026, and 2027, respectively, with price-to-sales ratios of 4.5, 3.7, and 3.2 times, indicating a strong value proposition compared to peers [5].

Core Viewpoint - Dongyang Sunshine Pharmaceutical has been awarded the "Annual Outstanding Biopharmaceutical Enterprise" at the "Technology Empowerment · Capital Breakthrough" sharing session, highlighting its achievements in innovation and research in the biopharmaceutical sector [1][3]. Company Overview - Dongyang Sunshine Pharmaceutical (06887.HK) is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generics, and biosimilars. The company emphasizes innovation, internationalization, and sustainability, driven by independent research and development [3]. - The company has established a comprehensive R&D system over 20 years, employing over 1,100 R&D personnel, including more than 20 foreign and returned experts. It has received the Guangdong Province Innovation Team title six times and holds over 2,500 patents [3][4]. Strategic Focus - The company adheres to "independent innovation" as its core strategy, deepening its "internationalization" efforts while focusing on three key therapeutic areas: infections, chronic diseases, and tumors. It employs diverse technologies, including small molecules, antibodies, small nucleic acids, ADC, and cell therapies [4]. - Dongyang Sunshine has launched three original innovative drugs and has 49 first-class innovative drugs in development, with one nearing market launch and ten in clinical phases II and III. Several pipeline products have "First in class" or "Best in class" potential [4]. Recent Achievements - In 2024, two candidate drugs are expected to achieve external cooperation and licensing agreements, with a total transaction value exceeding $1 billion [4]. - The company is addressing the global challenge of functional cure for hepatitis B with its small nucleic acid drugs and has the only complete independent intellectual property treatment plan for pan-genotype hepatitis C in China [4]. - Dongyang Sunshine's insulin product, Glargine, is set to be approved for sale in the U.S., making it the first Chinese company to market insulin in the U.S. Additionally, its new diabetes drug, Ologliptin, is also nearing approval [4].

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award was announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies were awarded, including Baillie Tianheng (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, listed in alphabetical order [1] Group 2: Evaluation Criteria - The evaluation for the award was based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were derived through quantitative data analysis and expert review [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award will be announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies, including Baillie Gifford (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, have been awarded the title [1] Group 2: Evaluation Criteria - The evaluation for the award is based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were determined through quantitative data analysis and an expert review panel [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]